Danzig Lisa
Clinical Research and Medical Affairs, Chiron Vaccines, Chiron Corporation, 4560 Horton Street, Emeryville, CA 94608, USA.
Vaccine. 2006 Apr 12;24 Suppl 2:S2-11-2. doi: 10.1016/j.vaccine.2005.01.103.
Although significant advances have been made toward the control of bacterial meningitis in children with the development of capsular polysaccharide protein conjugate vaccines, this approach has proven problematic for the serogroup B meningococcus. Non-capsular vaccines based upon outer membrane vesicles of Neisseria meningitidis have been useful in control of clonal serogroup B outbreaks, although due to variability of PorA, these vaccines may be less useful in control of endemic disease. Genome-based vaccine discovery was evaluated in an attempt to produce a candidate capable of conferring a broadly protective vaccine against a diversity of meningococcal B strains.
尽管随着荚膜多糖蛋白结合疫苗的研发，在控制儿童细菌性脑膜炎方面已取得重大进展，但这种方法已被证明对B群脑膜炎奈瑟菌存在问题。基于脑膜炎奈瑟菌外膜囊泡的非荚膜疫苗在控制B群克隆性暴发方面很有用，不过由于PorA的变异性，这些疫苗在控制地方性疾病方面可能效果较差。为了研制出一种能够针对多种B群脑膜炎奈瑟菌菌株提供广泛保护的候选疫苗，对基于基因组的疫苗研发进行了评估。
